Barclays Issues Positive Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price objective upped by Barclays from $10.00 to $12.00 in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has an overweight rating on the health services provider’s stock.

Several other brokerages have also issued reports on TDOC. Piper Sandler dropped their price target on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research note on Thursday, August 1st. Stifel Nicolaus decreased their price target on shares of Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, August 1st. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Finally, Royal Bank of Canada boosted their target price on Teladoc Health from $9.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Fourteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Teladoc Health currently has an average rating of “Hold” and an average target price of $11.86.

Teladoc Health Price Performance

NYSE:TDOC traded up $0.06 during trading hours on Thursday, hitting $9.06. 1,152,685 shares of the company’s stock traded hands, compared to its average volume of 5,449,852. Teladoc Health has a 52 week low of $6.76 and a 52 week high of $22.54. The business’s fifty day simple moving average is $8.41 and its two-hundred day simple moving average is $9.72. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The firm has a market cap of $1.55 billion, a P/E ratio of -1.55 and a beta of 0.91.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%. The company had revenue of $640.51 million for the quarter, compared to analysts’ expectations of $630.50 million. On average, research analysts anticipate that Teladoc Health will post -1.18 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In other news, CMO Stephany Verstraete sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total value of $114,000.00. Following the completion of the sale, the chief marketing officer now directly owns 45,158 shares in the company, valued at $343,200.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Teladoc Health news, Director Thomas Mckinley acquired 7,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was purchased at an average price of $7.57 per share, with a total value of $52,990.00. Following the completion of the purchase, the director now directly owns 31,077 shares in the company, valued at approximately $235,252.89. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Stephany Verstraete sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total transaction of $114,000.00. Following the completion of the sale, the chief marketing officer now owns 45,158 shares in the company, valued at approximately $343,200.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,588 shares of company stock worth $268,831. 0.95% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC lifted its position in Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock valued at $28,000 after purchasing an additional 1,715 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Teladoc Health during the second quarter worth $29,000. Blue Trust Inc. increased its position in shares of Teladoc Health by 84.5% during the third quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock worth $40,000 after acquiring an additional 1,854 shares during the period. Doheny Asset Management CA bought a new stake in Teladoc Health during the 2nd quarter valued at $46,000. Finally, SageView Advisory Group LLC purchased a new position in Teladoc Health during the 1st quarter valued at about $48,000. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.